Date Filed | Type | Description |
10/03/2023 |
4
| Robinson Chandler (CEO) has filed a Form 4 on Monopar Therapeutics
Txns:
| Paid exercise price by delivering 7,172 shares
@ $0.6199, valued at
$4.4k
Exercised 24,474 restricted stock units
@ $0 |
|
10/03/2023 |
4
| Tsuchimoto Kim R (CFO) has filed a Form 4 on Monopar Therapeutics
Txns:
| Paid exercise price by delivering 3,444 shares
@ $0.6199, valued at
$2.1k
Exercised 9,956 restricted stock units
@ $0 |
|
10/03/2023 |
4
| STARR CHRISTOPHER M (Director) has filed a Form 4 on Monopar Therapeutics
Txns:
| Exercised 2,533 restricted stock units
@ $0 |
|
10/03/2023 |
4
| KLAUSNER ARTHUR J (Director) has filed a Form 4 on Monopar Therapeutics
Txns:
| Exercised 2,533 restricted stock units
@ $0 |
|
10/03/2023 |
4
| Brown Michael J (Director) has filed a Form 4 on Monopar Therapeutics
Txns:
| Exercised 2,533 restricted stock units
@ $0 |
|
10/03/2023 |
4
| Anderson Raymond (Director) has filed a Form 4 on Monopar Therapeutics
Txns:
| Exercised 2,533 restricted stock units
@ $0 |
|
10/03/2023 |
4
| Cittadine Andrew (COO) has filed a Form 4 on Monopar Therapeutics
Txns:
| Paid exercise price by delivering 2,624 shares
@ $0.6199, valued at
$1.6k
Exercised 8,953 restricted stock units
@ $0 |
|
07/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
07/03/2023 |
4
| Anderson Raymond (Director) has filed a Form 4 on Monopar Therapeutics
Txns:
| Exercised 2,534 restricted stock units
@ $0 |
|
07/03/2023 |
4
| Brown Michael J (Director) has filed a Form 4 on Monopar Therapeutics
Txns:
| Exercised 2,534 restricted stock units
@ $0 |
|
07/03/2023 |
4
| KLAUSNER ARTHUR J (Director) has filed a Form 4 on Monopar Therapeutics
Txns:
| Exercised 2,534 restricted stock units
@ $0 |
|
07/03/2023 |
4
| STARR CHRISTOPHER M (Director) has filed a Form 4 on Monopar Therapeutics
Txns:
| Exercised 2,534 restricted stock units
@ $0 |
|
07/03/2023 |
4
| Tsuchimoto Kim R (CFO) has filed a Form 4 on Monopar Therapeutics
Txns:
| Paid exercise price by delivering 5,104 shares
@ $0.855, valued at
$4.4k
Exercised 14,846 restricted stock units
@ $0 |
|
07/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
04/04/2023 |
4
| STARR CHRISTOPHER M (Director) has filed a Form 4 on Monopar Therapeutics
Txns:
| Exercised 2,533 restricted stock units
@ $0 |
|
04/04/2023 |
4
| KLAUSNER ARTHUR J (Director) has filed a Form 4 on Monopar Therapeutics
Txns:
| Exercised 2,533 restricted stock units
@ $0 |
|
04/04/2023 |
4
| Brown Michael J (Director) has filed a Form 4 on Monopar Therapeutics
Txns:
| Exercised 2,533 restricted stock units
@ $0 |
|
04/04/2023 |
4
| Anderson Raymond (Director) has filed a Form 4 on Monopar Therapeutics
Txns:
| Exercised 2,533 restricted stock units
@ $0 |
|
04/04/2023 |
4
| Robinson Chandler (CEO) has filed a Form 4 on Monopar Therapeutics
Txns:
| Paid exercise price by delivering 4,286 shares
@ $1.39, valued at
$6k
Exercised 13,911 restricted stock units
@ $0 |
|
04/04/2023 |
4
| Tsuchimoto Kim R (CFO) has filed a Form 4 on Monopar Therapeutics
Txns:
| Paid exercise price by delivering 1,842 shares
@ $1.39, valued at
$2.6k
Exercised 5,067 restricted stock units
@ $0 |
|
04/04/2023 |
4
| Cittadine Andrew (COO) has filed a Form 4 on Monopar Therapeutics
Txns:
| Paid exercise price by delivering 1,154 shares
@ $1.39, valued at
$1.6k
Exercised 4,063 restricted stock units
@ $0 |
|
02/03/2023 |
4
| Anderson Raymond (Director) has filed a Form 4 on Monopar Therapeutics
Txns:
| Granted 13,930 options
@ $3.16, valued at
$44k
Granted 10,133 restricted stock units
@ $0 |
|
02/03/2023 |
4
| Brown Michael J (Director) has filed a Form 4 on Monopar Therapeutics
Txns:
| Granted 13,930 options
@ $3.16, valued at
$44k
Granted 10,133 restricted stock units
@ $0 |
|
02/03/2023 |
4
| Robinson Chandler (CEO) has filed a Form 4 on Monopar Therapeutics
Txns:
| Granted 221,839 options
@ $3.16, valued at
$701k
Granted 169,012 restricted stock units
@ $0 |
|
02/03/2023 |
4
| KLAUSNER ARTHUR J (Director) has filed a Form 4 on Monopar Therapeutics
Txns:
| Granted 13,930 options
@ $3.16, valued at
$44k
Granted 10,133 restricted stock units
@ $0 |
|
02/03/2023 |
4
| Tsuchimoto Kim R (CFO) has filed a Form 4 on Monopar Therapeutics
Txns:
| Granted 102,688 options
@ $3.16, valued at
$324.5k
Granted 78,234 restricted stock units
@ $0 |
|
02/03/2023 |
4
| Cittadine Andrew (COO) has filed a Form 4 on Monopar Therapeutics
Txns:
| Granted 102,688 options
@ $3.16, valued at
$324.5k
Granted 78,234 restricted stock units
@ $0 |
|
02/03/2023 |
4
| STARR CHRISTOPHER M (Director) has filed a Form 4 on Monopar Therapeutics
Txns:
| Granted 13,930 options
@ $3.16, valued at
$44k
Granted 10,133 restricted stock units
@ $0 |
|
01/03/2023 |
4
| Anderson Raymond (Director) has filed a Form 4 on Monopar Therapeutics
Txns:
| Exercised 2,859 restricted stock units
@ $0 |
|
01/03/2023 |
4
| Brown Michael J (Director) has filed a Form 4 on Monopar Therapeutics
Txns:
| Exercised 2,859 restricted stock units
@ $0 |
|
01/03/2023 |
4
| KLAUSNER ARTHUR J (Director) has filed a Form 4 on Monopar Therapeutics
Txns:
| Exercised 2,859 restricted stock units
@ $0 |
|
01/03/2023 |
4
| STARR CHRISTOPHER M (Director) has filed a Form 4 on Monopar Therapeutics
Txns:
| Exercised 2,859 restricted stock units
@ $0 |
|
01/03/2023 |
4
| Cittadine Andrew (COO) has filed a Form 4 on Monopar Therapeutics
Txns:
| Paid exercise price by delivering 1,406 shares
@ $2.37, valued at
$3.3k
Exercised 4,062 restricted stock units
@ $0 |
|
01/03/2023 |
4
| Tsuchimoto Kim R (CFO) has filed a Form 4 on Monopar Therapeutics
Txns:
| Paid exercise price by delivering 2,067 shares
@ $2.37, valued at
$4.9k
Paid exercise price by delivering 502 shares
@ $2.37, valued at
$1.2k
Exercised 5,067 restricted stock units
@ $0 Exercised 1,230 restricted stock units
@ $0 |
|
|